Irisin Lowers Blood Pressure by Improvement of Endothelial Dysfunction via AMPK-Akt-eNOS-NO Pathway in the Spontaneously Hypertensive Rat

Jinjuan Fu
Yu Han
Jialiang Wang
Yukai Liu
Shuo Zeng

See next page for additional authors
Authors
Jinjuan Fu, Yu Han, Jialiang Wang, Yukai Liu, Shuo Zeng, Lin Zhou, Pedro A. Jose, and Chunyu Zeng
Irisin Lowers Blood Pressure by Improvement of Endothelial Dysfunction via AMPK-Akt-eNOS-NO Pathway in the Spontaneously Hypertensive Rat

Jinjuan Fu, MD;* Yu Han, BS;* Jialiang Wang, MS; Yukai Liu, MD; Shuo Zheng, BS; Lin Zhou, MD, PhD; Pedro A. Jose, MD, PhD; Chunyu Zeng, MD, PhD

Background—Exercise is a major nonpharmacological treatment for hypertension, but its underlying mechanisms are still not completely elucidated. Irisin, a polypeptide containing 112 amino acids, which is secreted mainly by skeletal muscle cells during exercise, exerts a protective role in metabolic diseases, such as diabetes mellitus and obesity. Because of the close relationship between irisin and metabolic diseases, we hypothesized that irisin may play a role in the regulation of blood pressure.

Methods and Results—Blood pressures of male Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs) were monitored through the carotid artery. Our study found that acute intravenous injection of irisin reduced blood pressure in SHRs, but not WKY rats. Irisin, by itself, had no direct vasorelaxing effect in phenylephrine-preconstricted mesenteric arteries from SHRs. However, irisin augmented the acetylcholine-induced vasorelaxation in mesenteric arteries from SHRs that could be reversed by resistin, and many diseases are closely related to its disorder.8 It has been reported that more than 1000 genes are “activated” by exercise training in human skeletal muscle, all of which may

Conclusions—we conclude that acute administration of irisin lowers blood pressure of SHRs by amelioration of endothelial dysfunction of the mesenteric artery through the AMPK-Akt-eNOS-NO signaling pathway. (J Am Heart Assoc. 2016;5: e003433 doi: 10.1161/JAHA.116.003433)

Key Words: 5-AMP-activated protein kinase • hypertension • irisin • nitric oxide • vasorelaxation
Irisin Lowers Blood Pressure in the Spontaneously Hypertensive Rat
Fu et al

Contribute to improvement in health.\(^9\,^1\) Recently, a newly found exercise-mediated polypeptide called irisin, the cleavage of extra cellular domain of fibronectin type III domain-containing 5 protein (FNDC5), has drawn a lot of attention.\(^1\) Exercise can upregulate transcription factor PPAR\(\gamma\) coactivating factor 1\(x\), which promotes muscle-derived FNDC5 expression and then releases irisin into the circulation to increase body energy expenditure.\(^2\,^3\) Both FNDC5 and irisin are decreased in patients with type 2 diabetes mellitus (T2DM), and irisin has been reported to be beneficial in glucose homeostasis, insulin resistance, and related morbidities, including obesity.\(^4\) Because of the close relationship between metabolic diseases and hypertension, it is possible that exercise, through the myogenic factor, irisin,\(^5\) may lower blood pressure.

Zhang et al and Jiang et al have reported that irisin (0.1–100 \(\mu\)mol/L) caused endothelium-dependent and – independent vasodilation of arteries preconstricted with phenylephrine in mice and rats.\(^1\) Zhang et al also reported that bolus injections (2 minutes) of high doses of irisin (0.625–4 \(\mu\)g) decreased the blood pressure of Sprague-Dawley and spontaneously hypertensive rats (SHRs).\(^2\) In humans, the circulating concentration of irisin is 3.6 ng/mL in sedentary individuals and increases to 4.3 ng/mL in individuals undergoing aerobic interval training.\(^1\) The circulating concentration of irisin in rats detected by ELISA is around 300 to 600 ng/mL.\(^3\) Therefore, in the present study, we studied the effect of low doses of irisin on blood pressure and low concentrations of irisin on arterial relaxation in normotensive Wistar-Kyoto (WKY) and SHRs.

Mammalian AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase that has been proposed to function as an intracellular energy sensor and is involved in the regulation of cellular and whole-body metabolism.\(^2\) Nitric oxide (NO) is one of the most important factors for the relaxation of blood vessels and changes in NO bioavailability affect blood flow and arterial blood pressure. In the vasculature, activation of endothelial AMPK has been shown to phosphorylate eNOS\(^1\)\(^7\)\(^7\), stimulating NO release and subsequent vasodilatation of both large conduit and resistance arteries.\(^3\) The endothelium-dependent mesenteric arterial relaxation in mice attributed to high concentrations (0.1–100 \(\mu\)mol/L) of irisin has also been reported to be related to the NO-cGMP pathway. Therefore, our present study was designed to determine whether the AMPK-eNOS-NO pathway is involved in the vasorelaxing effect of irisin in SHRs.

Material and Methods

Blood Pressure Measurement

Male WKY and SHRs (SLRC Laboratory Animals, Shanghai, China), ranging in age from 16 to 18 weeks, were fed a regular and normal sodium (1% NaCl) rat chow. To empty the stomach and prevent food reflux into the respiratory tract under general anesthesia, food, but not water, was withheld 12 hours before the study. Before the performance of the experiments, rats were anesthetized with pentobarbital (50 mg/kg body weight, intraperitoneally), placed on a heated table to maintain rectal temperature between 36° and 37°, and tracheotomized (PE-240). Catheters (PE-50) were placed into both external jugular veins, which were used for maintaining anesthesia and irisin injection. Anesthesia was maintained by the infusion of pentobarbital sodium at 0.8 mg/100 g body weight per hour.\(^2\) Catheters (PE-50) were also placed inside the carotid artery for monitoring systemic arterial pressure (Cardiomax II; Columbus Instruments, Columbus, OH). After achieving stable hemodynamic conditions and recording of baseline blood pressures for 5 minutes, rats received an intravenous injection of irisin (0.1, 1, or 10 \(\mu\)g/kg, bolus injection) or heat-denatured irisin. To determine the role of eNOS on the hypotensive effect of irisin, rats were pretreated with a bolus injection of the eNOS inhibitor, N\(\text{o}\)-nitro-L-arginine-methyl ester (L-NAME; 30 mg/kg),\(^2\) and stable baseline blood pressure and heart rate were recorded for 10 minutes.\(^2\) Following the bolus injection of L-NAME, rats received either the vehicle (1% DMSO in 0.9% NaCl) or an identical series of irisin injections as above; blood pressure and heart rate were recorded for 60 minutes. All studies were approved by the Daping Hospital Animal Care and Use Committee.

Preparation and Study of Small Resistance Arteries

Vascular reactivity was determined as previously described.\(^2\) Briefly, the third-order branches of the mesenteric arteries were dissected and cut in segments of \(\approx 2\) mm in length and mounted on 40-\(\mu\)m stainless-steel wires in an isometric Mulvany-Halpern small-vessel myograph (model 91 M610; J.P. Trading, Aarhus, Denmark). Rings were maintained in physiological saline solution (PSS) at 37°C and continuously bubbled with oxygen (95%) and carbon dioxide (5%; Carbogen). After a 15-minute equilibration period in oxygenated PSS at 37°C and pH 7.4, arterial segments were stretched to the optimal luminal diameter for active tension development. Then, vessels were rinsed 3 times with fresh PSS and allowed to recover to baseline for 30 minutes. In the first set of experiments, rings were contracted with phenylephrine HCl (PHE; 10 \(\mu\)mol/L) and high-potassium PSS (125 mmol/L).

To study acetylcholine (Ach)-induced endothelium-dependent relaxation, mesenteric arterial segments were rinsed with PSS for 30 minutes and then a cumulative concentration-response curve to Ach (1 nmol/L to 100 mmol/L) was obtained in PHE-preconstricted segments preincubated in the absence or presence of irisin (600 ng/mL).
Irisin Lowers Blood Pressure in the Spontaneously Hypertensive Rat  
Fu et al

[48 nmol/L] or 3000 ng/mL [240 nmol/L], 1 hour) and the procedure was repeated with PSS containing sodium nitroprusside (SNP; 1–1000 nmol/L). To study the effect of irisin on vasoconstriction, a cumulative concentration response to PHE (1 nmol/L to 10 μmol/L) was obtained in arterial segments preincubated in the absence or presence of irisin (3000 ng/mL, 1 hour). The possible role of NO in Ach-mediated vasodilation was investigated in irisin-treated and -untreated arterial segments by preincubation with L-NNAME (100 μmol/L, 30 minutes) before studying concentration response to Ach. In addition, the participation of cyclooxygenase (COX)-mediated vasorelaxation was investigated in irisin-treated and -untreated segments. Arteries were preincubated with the nonspecific COX inhibitor indomethacin (10 μmol/L) before performing concentration-response studies to Ach. In addition, the role of endothelium-derived hyperpolarizing factor (EDHF) in the Ach-induced relaxation was analyzed. For this purpose, the vasodilator response to Ach in segments precontracted with high K⁺ solution (60 mmol/L of KCl) was studied.  

In some experiments, the role of AMPK in Ach-induced relaxation was investigated in irisin-treated and -untreated segments by preincubation with the AMPK inhibitor, compound C (CC; 20 μmol/L) for 30 minutes before studying the concentration response to Ach.

Evaluation of Intracellular NO Levels With DAF-2 DA

Human coronary artery endothelial cells were seeded into cell-culture dishes. After cells achieved 60% confluence, supernatants were removed and then washed 3 times in 1 mL of HEPES buffer (119 mmol/L of NaCl, 20 mmol/L of Na-HEPES [pH 7.4], 5 mmol/L of NaHCO₃, 4.7 mmol/L of KCl, 1.3 mmol/L of CaCl₂, 1.2 mmol/L of MgSO₄, 1 mmol/L of KH₂PO₄, 100 μmol/L of l-arginine, and 5 mmol/L of glucose) at 37°C. Thereafter, cells were incubated with an NO-sensitive dye, 4,5-diaminofluorescein diacetate (DAF-2 DA; 10 μmol/L) for 45 minutes in the dark at 37°C. After loading, cells were rinsed 3 times with HEPES buffer. The concentration of NO in cells was measured using a DAF-2 DA fluorescence assay. Some assays were performed in the presence of L-NNAME (100 μmol/L) throughout the experimental period. Fluorescence was measured with the excitation wavelength set at 495 nm and the emission wavelength at 515 nm, using fluorescence microscopy (Olympus America, Inc., Melville, NY). NO fluorescence was measured every 20 seconds for 10 to 15 minutes in the same area of the endothelial surface. Basal fluorescence intensity was recorded before each experiment.

NO Assay

Endothelial cells from human coronary artery were grown on 6-well plates, and experiments were performed 24 hours after cells reached confluence and serum starved for 3 hours, then stimulated with irisin (3000 ng/mL, 10 minutes). Concentrations of NO metabolites nitrite and nitrate in the cell-culture supernatant were determined using an assay based on the enzymatic conversion of nitrate to nitrite by nitrate reductase, followed by colorimetric detection of nitrite as an azo-dye product of the Griess reaction (R&D Systems; Minneapolis, MN). All samples were centrifuged to remove particulates at
16 000g for 20 minutes at 4°C.33 One hundred microliters of each supernatant were mixed with 100 μL of the Griess reagent for 10 minutes at 37°C, and absorbance was recorded on a 96-well plate using Thermo Scientific Varioskan Flash (Thermo LabSystems, Inc., Philadelphia, PA) at 540 nm.34 Total nitrite levels were determined using a standard curve. NO production is expressed as μmol/L.

Additional Materials

PHE, Ach, SNP, L-NAME and CC, indomethacin, HEPES, and DMSO were obtained from Sigma-Aldrich (St. Louis, MO). Irisin polypeptide and antibody for irisin were from Phoenix Pharmaceuticals, Inc (Burlingame, CA), and anti-FNDC5 rabbit polyclonal antibody was from Proteintech (Wuhan, China). Antibodies for total AMPKα1, phosphorylated AMPKα1, total Akt, phosphorylated Akt, total eNOS, phosphorylated eNOS, total nNOS, phosphorylated nNOS, and GAPDH were from Cell Signaling Technology. Infrared-labeled donkey antirabbit IRDye 800 was from Li-Cor Biosciences. DAF-2 DA was from Calbiochem (San Diego, CA). Cell-culture dishes were from NEST Biotechnology Co. LTD (Rahway, NJ). The Griess reagent system was from R&D Systems.

Statistical Analyses

Data are expressed as mean±SD. For assays involving arterial rings, the number (n) refers to the number of rats, each providing 2 to 3 rings. Relaxation in each arterial segment is expressed as the percentage of the contraction induced by PHE (10 μmol/L). PHE-induced contraction in each arterial segment is expressed as the percentage of the contraction induced by 60 mmol/L of KCl. Comparison within groups was made by repeated-measures ANOVA (or paired t test when only 2 groups were compared), and comparison among groups was made by factorial ANOVA with the Holm-Sidak test (or t test when only 2 groups were compared). A value of P<0.05 was considered significant.

Results

Irisin Lowered Blood Pressure by Improvement of Endothelial Dysfunction in SHR

Irisin decreased blood pressure in a dose-dependent (0.1, 1, and 10 μg/kg) manner in SHRs. By contrast, in WKY rats, irisin had no effect on blood pressure (Figure 1A). Zhang et al also did not find an effect of 1 μg (equivalent to 4 μg/kg in a 250-g rat), but found that 2 μg (equivalent to 8 μg/kg in a 250-g rat) of irisin slightly decreased blood pressure of normotensive Sprague-Dawley rats.17 Zhang et al also found that irisin decreased blood pressure in a dose-dependent fashion in SHRs (2, 4, and 8 μg, equivalent to 8, 16, 32 μg/kg in a 250-g rat).17 In SHRs, the bolus intravenous injection of irisin (10 μg/kg) started to decrease blood pressure after
5 minutes, reached significance after 10 minutes, with the maximum effect noted after 20 minutes; the vasodepressor effect of irisin was no longer evident at 90 minutes. Heat-denatured irisin had no effect on blood pressure (Figure 1B). Irisin, also, had no effect on heart rate (Figure 1C).

We next determined whether irisin has any vasorelaxant effect in mesenteric arteries. Irisin (3000 ng/mL), by itself, had no direct vasorelaxant effect in mesenteric arteries from SHRs (Figure 2A1) and WKY rats (Figure 2A2), preconstricted with PHE. However, it augmented Ach-mediated vasorelaxation in mesenteric arteries from SHRs (Figure 2B), but not WKY rats (Figure 2E). We also found that irisin could decrease the vasoconstriction induced by PHE in the mesenteric artery of SHRs (Figure 2D). SNP, an exogenous NO donor, induces endothelium-independent vasorelaxation. We found that there was no additive effect of irisin on SNP-induced vasorelaxation in mesenteric arteries from both SHRs (Figure 2C) and WKY rats (Figure 2F). Those results indicate that...
vascular dysfunction in SHRs can be ameliorated by irisin in an endothelium-dependent mechanism.

**Irisin-Mediated Increase in NO Production Decreased Endothelial Dysfunction in the Mesenteric Artery of the SHR**

NO produced in Ach-induced vasodilation is from endothelial cells, and irisin-evoked relaxation of mesenteric arteries from mice has been reported to be partially blocked by the NOS inhibitor, L-NAME.18 Because the irisin sequence is highly conserved among species,36 we determined the effect of irisin on NO production in human coronary endothelial cells. Irisin increased NO production, measured by DAF-2 DA fluorescence28,32 staining, in a time- and concentration-dependent (Figure 3A1 and 3A2) manner. L-NAME (100 μmol/L), an NOS inhibitor, completely abrogated the irisin-induced increase in NO production (Figure 3B1 and 3B2). To further confirm the results, another method to measure NO metabolites (ie, nitrite and nitrate) was used; consistent with results in Figure 3B, irisin (3000 ng/mL, 10 minutes) increased NO production, whereas pretreatment with L-NAME (100 μmol/L) abolished the stimulatory effect of irisin on NO production (Figure 3C). In additional studies, human coronary endothelial cells were preincubated with irisin (3000 ng/mL) for 1 hour, washed with HEPES buffer, and then treated with Ach (100 nmol/L). We found that irisin (3000 ng/mL) increased the ability of Ach (100 nmol/L) to increase NO production after 240 seconds of incubation (Figure 3D1 and 3D2).

We, next, evaluated the effect of irisin on eNOS-ser\(^{1177}\) phosphorylation (p-eNOS) levels in rat mesenteric arteries from SHRs and human coronary endothelial cells. In the mesenteric arteries, as compared to controls, irisin (600 ng/mL) incubation for 30 minutes significantly stimulated eNOS-ser\(^{1177}\) phosphorylation26 as early as 15 minutes, peaked at 60 minutes, and then gradually decreased close to the basal level at 240 minutes (Figure 3E). Irisin (30-minute incubation) also increased eNOS-ser\(^{1177}\) phosphorylation in a concentration-dependent manner (Figure 3F). Irisin (600 ng/mL) incubation also stimulated eNOS-ser\(^{1177}\) phosphorylation in human coronary endothelial cells similar to the rat mesenteric arteries, but the effect occurred later, that is, 30 minutes (Figure 3G). Although eNOS is the isoform of NOS that is mainly expressed in endothelial cells,37,38 we also assessed the effects of irisin on nNOS phosphorylation in human aortic endothelial cells, and found that, although the expression of nNOS was weaker than eNOS, irisin, at a 600-ng/mL concentration, also increased nNOS phosphorylation at 60 minutes (Figure 3H).

The effect of irisin on NO production is physiologically significant, because the synergistic vasorelaxant effect of irisin and Ach was blocked by the NOS inhibitor, L-NAME (100 μmol/L; Figure 4A) but not by inhibitors of COX and EDHF, indomethacin (10 μmol/L), and KCl (60 mmol/L), respectively (Figure 4B and 4C). Moreover, the blood-pressure-lowering effect of irisin in SHRs was almost completely blocked by pretreatment with L-NAME (30 mg/kg, bolus injection; Figure 4D).

**Irisin Phosphorylates eNOS Through Upregulation of AMPK and Akt Phosphorylation in Human Coronary Endothelial Cells**

To elucidate the mechanisms underlying the increase in eNOS phosphorylation in response to irisin, AMPK and Akt, the upstream transducers of eNOS phosphorylation, were evaluated. As shown in Figure 5A through 5C, irisin increased AMPK (Thr\(^{172}\)) and Akt (Ser\(^{473}\)) phosphorylation in a concentration- and time-dependent manner, but had no effect on total AMPK and Akt. An additional study showed that in the presence of CC (20 μmol/L), an AMPK inhibitor, the irisin-mediated increase in phosphorylations of Akt and eNOS were blocked (Figure 6A1 through 6A4). Moreover, pretreatment with CC partially blocked the synergistic vasorelaxant effect of irisin and Ach (Figure 6B).

**Discussion**

Exercise training lowers blood pressure and is a recommended nonpharmacological therapy for hypertension, but the mechanisms involved remain elusive. Studies have shown that exercise training attenuates aortic remodeling and improves endothelial function caused by skeletal muscle–derived factors.3,39 Since its discovery, irisin has gained great interest as an agent to combat obesity, T2DM, and other metabolic diseases.40–43 Irisin has been reported to promote human umbilical vein endothelial cell (HUVEC) proliferation and angiogenesis through the extracellular signal-related kinase signaling pathway and partially suppress high-glucose–induced apoptosis.44,45 Circulating irisin levels are positively associated with endothelium-dependent vasodilation in patients with newly diagnosed T2DM without clinical angiopathy.46 Because metabolic diseases and endothelial dysfunction are associated with hypertension, we studied the effect of irisin in the regulation of blood pressure. We found that bolus intravenous administration of irisin decreases blood pressure, but had no direct vasorelaxing effect. Instead, as shown in Figure 7, irisin ameliorates the endothelial dysfunction of the mesenteric artery of SHRs, by increasing in NO production and activating the AMPK-Akt-eNOS pathway.

In humans, the circulating concentration irisin detected by mass spectrometry is 3.6 ng/mL in sedentary individuals and increases to 4.3 ng/mL in individuals undergoing aerobic...
Figure 3. Effect of irisin on NO production and eNOS phosphorylation in mesenteric arteries from spontaneously hypertensive rats (SHRs) and human coronary endothelial cells. A, Effect of irisin on NO production in human coronary endothelial cells. NO production was examined after irisin or vehicle treatment of endothelial cells. Representative experiments are shown at time point 0, 240, and 480 seconds in (A1). The summary of the data and statistical analysis is shown in (A2) (*P<0.05 vs vehicle; n=4). B, Effect of eNOS on irisin-mediated NO production in human coronary endothelial cells. Human coronary endothelial cells were preincubated with L-NAME (100 μmol/L, 30 minutes) and then treated with irisin (3000 ng/mL). Representative experiments are shown in (B1). The summary of the data and statistical analysis is shown in (B2) (*P<0.05 vs L-NAME-treated group; n=4). C, Effect of irisin on NO production, determined by measurement of nitrite and nitrate contents in the cell-culture medium of human coronary endothelial cells. Endothelial cells were treated with irisin (3000 ng/mL, 10 minutes) in the presence or absence of an NOS inhibitor (L-NAME, 100 μmol/L) for 30 minutes. Medium was then collected for NO metabolite nitrite and nitrate detection (*P<0.05 vs control group; #P<0.05 vs irisin; n=4). D, Effect of irisin on Ach-stimulated NO production in human coronary endothelial cells. Preincubation of irisin (3000 ng/mL) for 1 hour in human coronary endothelial cells increases Ach-induced (100 nmol/L) production of NO. Representative experiments are shown in (D1). The summary of the data and statistical analysis is shown in (D2) (*P<0.05 vs Ach group; n=4). E and F, Effect of irisin on eNOS phosphorylation in the mesenteric artery from SHRs. Mesenteric arteries were incubated with irisin at the indicated concentrations and periods. Results are expressed as the ratio of phosphorylated eNOS to total eNOS (*P<0.05 vs control group; n=4). G and H, Effect of irisin on eNOS phosphorylation (G) and nNOS phosphorylation (H) in human coronary endothelial cells. Endothelial cells were incubated with irisin at the indicated concentrations and periods. Results are expressed as the ratio of phosphorylated eNOS and nNOS to total eNOS and nNOS (*P<0.05 vs control group, n=4). Ach indicates acetylcholine; DAF-2 DA, 4,5-diaminofluorescein diacetate; DU, density units; eNOS, endothelial nitric oxide synthase; L-NAME, No-nitro-L-arginine methyl ester; nNOS, neural nitric oxide synthase; NO, nitric oxide. RU, relative units.
interval training. The circulating concentration of irisin in the rat detected by ELISA is around 300 to 600 ng/mL. Therefore, we chose 600 ng/mL to study the effect of irisin on the function of rat mesenteric artery.

It is well known that Ach induces vasorelaxation through endothelium-derived relaxing factors that include NO, prostacyclin (prostaglandin I₂; PGI₂), and EDHF. Therefore, the NO inhibitor, L-NAME, and COX inhibitor, indomethacin, were used to determine whether or not the increase in Ach-induced vasodilation induced by irisin is attributed to NO or prostaglandins. The vasorelaxation induced by EDHF is endothelium-dependent opening of K⁺ channels that leads to hyperpolarization of vascular smooth muscle cells.

In order to determine whether or not the increase in Ach-induced vasodilation induced by irisin is attributed to an increase in EDHF activity, mesenteric resistance arteries were precontracted with a high K⁺ solution (60 mmol/L). Our results suggest that the vasodilatory synergism of irisin and Ach can be blocked by L-NAME, indicating the involvement of NO. After preincubation with indomethacin or 60 mmol/L of L-NAME injection, irisin or Vehicle injection

**Figure 4.** Role of NO, PGI₂, and EDHF on the irisin-mediated augmentation of Ach-mediated effect in the mesenteric artery of the spontaneously hypertensive rat (SHR). A and B, Role of NO (A) or PGI₂ (B) in the augmented effect of irisin on Ach-mediated vasodilation in the mesenteric artery of the SHR. PHE-precontracted mesenteric artery segments from SHRs were preincubated with irisin (3000 ng/mL, 1 hour) and then incubated with different concentrations of Ach (1–100 nmol/L). The irisin-mediated augmentation of Ach-mediated vasodilation was evaluated with or without L-NAME (100 μmol/L, 30 minutes) (A) or indomethacin (10 μmol/L) (B). (A, n=6; *P<0.05 vs control; #P<0.05 vs irisin; ##P<0.05 vs indomethacin; n=6). C, Role of EDHF in the augmented effect of irisin on Ach-mediated vasodilation in the mesenteric artery of the SHR. Mesenteric artery was precontracted with PHE in the presence or absence of KCl (60 mmol/L) and then treated with Ach with or without preincubation with irisin (3000 ng/mL; 1 hour; *P<0.05 vs irisin [KCl]; †P<0.05 vs control group; n=6). D, Role of eNOS on irisin-mediated blood pressure lowering effect in the SHR. SHRs were treated with L-NAME (30 mg/kg, bolus injection) and then irisin (10 μg/kg, bolus injection). The effect of irisin on systolic blood pressure (SBP) was monitored (n=5; P=NS). Ach indicates acetylcholine; EDHF, endothelium-derived hyperpolarizing factor; eNOS, endothelial nitric oxide synthase; L-NAME, NO-nitro-L-arginine methyl ester; NO, nitric oxide; NS, not significant. PHE, phenylephrine.
K⁺ solution, ACh-induced relaxation was decreased to a similar extent in both experimental conditions, indicating that the synergistic vasorelaxation effect of irisin with Ach in SHR is independent of EDHF and COX pathways. Although irisin has been reported to dilate rat mesenteric arteries through ATP-sensitive potassium channels, this effect was noted at micromolar concentrations of irisin, much higher than the nanomolar concentrations of circulating irisin, used in the current report. The ability of higher concentrations of irisin to relax mouse mesenteric arteries has also been reported to be independent of PGI₂. In additional studies, we found that irisin concentration- and time-dependently enhanced the phosphorylation of eNOS from endothelial cells and mesenteric arteries, an effect that was blocked by L-NAME. Moreover, pretreatment with L-NAME to block NOS almost completely prevented the blood-pressure-lowering effect of irisin in SHRs. Endothelial cells express eNOS to a greater extent than other NOS isoforms, including nNOS. Although we also found that irisin could stimulate the phosphorylation of nNOS, its effect was weaker than eNOS. Thus, all pieces of evidence show a role of NO, presumably generated mainly by eNOS, in the irisin-mediated amelioration of endothelial dysfunction and high blood pressure.

At present, various methods have been proposed to detect NO production inside or outside living organisms. Fluorescent dyes, like DAF-2DA, are the direct way to quantify NO production and are still widely used, although doubts about its specificity have recently been raised. Those studies provide evidence that DAF-2DA dyes react not only with NO, but also with peroxidase enzyme and hydrogen peroxide; both are secreted in the case of elicitation of suspension cells, with a fluorescence increase mimicking NO release from cells. Besides, NO has an extremely short half-life; therefore, it is difficult to detect NO production in so short a time. Because of the above-mentioned limitation, scientists realize that measurement of NO metabolites (ie, nitrite and nitrate) might be an alternative method, determined by the Griess reaction method, chemiluminescence, or high-performance liquid chromatography (HPLC). Among these methods, HPLC, with the advantages of high sensitivity, was widely applied recently. Because of the lack of HPLC equipment, we used DAF-2 DA fluorescent dye.

Figure 5. Effect of irisin on AMPK and Akt phosphorylation in human coronary endothelial cells. Endothelial cells were incubated with irisin at the indicated concentrations and times. Phospho-AMPKα₁ (A and B) and phospho-Akt (C) results were normalized by total AMPKα₁ and Akt, respectively (*P<0.05 vs control group; n=4). Akt indicates protein kinase B; AMPK, AMP-activated protein kinase; DU, density units; p, phospho.

DOI: 10.1161/JAHA.116.003433
probes and the Griess reaction method to determine NO production instead in the present study. We found that irisin increased NO production, whereas pretreatment with L-NAMEabolished the stimulatory effect of irisin on NO production, which is consistent with other reports; for example, Han et al found that irisin could stimulate NO production in HUVECs.54

AMPK has been characterized as an energy sensor (sensitive to the AMP/ATP ratio) in the regulation of glucose uptake and fatty acid oxidation in the whole body.22,57 AMPK is involved in endothelial cell homeostasis.58,59 The principal AMPK catalytic subunit isoform contributing to AMPK activity in endothelial cells is the α1 isoform.60 Previous studies have shown that AMPK induces phosphorylation of eNOS at serine-1177 and activates NO generation in endothelial cells.61,62 A recent study also found that high concentrations of AMPK agonist also dilate resistance arteries through activation of SERCA and BKCa channels in smooth muscle.63 Irisin promotes the synthesis of uncoupling protein 1 (UCP1) in brown fat cells,12 and UCP1 causes bioenergetically uncoupled energy dissipation (heat production, thermogenesis).64

Exercise activates AMPK in skeletal muscle and endothelial cells.65,66 In our present study, we found that exogenous irisin dose- and time-dependently enhances the phosphorylation of AMPK. Inhibition of AMPK prevents the irisin-mediated phosphorylation of eNOS and Akt. We also found that inhibition of AMPK partially blocks the irisin-mediated increase in Ach-induced relaxation of mesenteric artery. Therefore, AMPK/Akt/eNOS/NO is involved in the vasodilatory effect of irisin.

In conclusion, we found that low doses or physiological concentrations of irisin did not lower blood pressure or dilate the mesenteric artery of WKY rats. By contrast, irisin decreased blood pressure of SHRs in a concentration-dependent manner. Physiological concentrations of irisin (48 and 240 nmol/L) did not dilate the mesenteric artery of SHRs precontracted by PHE. However, the same concentration of irisin ameliorated the impaired-endothelial relaxation response to Ach in the mesenteric artery of the SHR. The vasodilatory effect of irisin was caused by the stimulation of arterial endothelial cells to increase AMP/ATP levels and NO.
Figure 7. Schematic illustration of the proposed signaling mechanism involved in irisin-mediated vasorelaxation and lowering blood pressure in the spontaneously hypertensive rat (SHR). During exercise, the skeletal muscles release irisin into the circulation, which acts on arterial endothelial cells to increase AMP/ATP levels and NO release by activation of AMPK and Akt. The upregulation of NO ameliorates endothelial dysfunction and, ultimately, decreases blood pressure. Akt indicates protein kinase B; AMPK, AMP-activated protein kinase; NO, nitric oxide; p, phospho.

release by activation of AMPK and Akt. Upregulation of NO production improved the endothelial dysfunction in the SHR and ultimately decreased blood pressure, which may be helpful to normalize the high blood pressure of hypertensive patients.

Sources of Funding
These studies were supported, in part, by grants from the National Natural Science Foundation of China (31430043, 31130029, National International Technology Special Grant (2014DFA31070), and National Basic Research Program of China (2013CB531104).

Disclosures
None.

References


50. Qi D, Young LH. AMPK: energy sensor and survival mechanism in the ischemic heart. Trends Endocrinol Metab. 2015;26:422–429.


Irisin Lowers Blood Pressure by Improvement of Endothelial Dysfunction via AMPK–Akt–
eNOS–NO Pathway in the Spontaneously Hypertensive Rat
Jinjuan Fu, Yu Han, Jialiang Wang, Yukai Liu, Shuo Zheng, Lin Zhou, Pedro A. Jose and Chunyu
Zeng

*J Am Heart Assoc.* 2016;5:e003433; originally published October 26, 2016;
doi: 10.1161/JAHA.116.003433

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue,
Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://jaha.ahajournals.org/content/5/11/e003433

Subscriptions, Permissions, and Reprints: The *Journal of the American Heart Association* is an online only Open